WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H575602
CAS#: 914613-86-8 (strontium anhydrous)
Description: Esomeprazole strontium anhydrous is a biochemical with gastric proton pump inhibitor activity.
Hodoodo Cat#: H575602
Name: Esomeprazole strontium anhydrous
CAS#: 914613-86-8 (strontium anhydrous)
Chemical Formula: C34H36N6O6S2Sr
Exact Mass: 776.12
Molecular Weight: 776.440
Elemental Analysis: C, 52.60; H, 4.67; N, 10.82; O, 12.36; S, 8.26; Sr, 11.28
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 161796-78-7(sodium) 119141-88-7(free) 161973-10-0 (magnesium) 217087-09-7 (magnesium hydrate) 161796-84-5 (potassium) 914613-86-8 (strontium anhydrous)
Synonym: Esomeprazole strontium anhydrous; Fm0F67 anhydrous
IUPAC/Chemical Name: 1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, strontium salt
InChi Key: FEVPVZSYBDUVGY-YPPDDXJESA-N
InChi Code: InChI=1S/2C17H18N3O3S.Sr/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3;/q2*-1;+2/t2*24-;/m00./s1
SMILES Code: [Sr+2].COc1ccc2[n-]c(nc2c1)[S@@](=O)Cc3ncc(C)c(OC)c3C.COc4ccc5[n-]c(nc5c4)[S@@](=O)Cc6ncc(C)c(OC)c6C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 776.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Lotfy HM, Amer SM, Zaazaa HE, Mostafa NS. A comparative study of the novel spectrophotometric methods versus conventional ones for the simultaneous determination of Esomeprazole magnesium trihydrate and Naproxen in their binary mixture. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Dec 5;151:538-46. doi: 10.1016/j.saa.2015.07.007. Epub 2015 Jul 3. PubMed PMID: 26162342.
2: Kan SL, Lu J, Liu JP, Zhao Y. Preparation and in vitro/in vivo evaluation of esomeprazole magnesium-modified release pellets. Drug Deliv. 2015 Jul 21:1-8. [Epub ahead of print] PubMed PMID: 24892629.
3: Kumar P, Ganure AL, Subudhi BB, Shukla S. Preparation and characterization of pH-sensitive methyl methacrylate-g-starch/hydroxypropylated starch hydrogels: in vitro and in vivo study on release of esomeprazole magnesium. Drug Deliv Transl Res. 2015 Jun;5(3):243-56. doi: 10.1007/s13346-015-0221-7. PubMed PMID: 25787732.
4: Liu Z, Wang W, Chen H, Liu J, Zhang W. Novel application method of talcum powder to prevent sticking tendency and modify release of esomeprazole magnesium enteric-coated pellets. Pharm Dev Technol. 2015 Feb 24:1-10. [Epub ahead of print] PubMed PMID: 25708151.
5: Choi Y, Han H, Shin D, Lim KS, Yu KS. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. Drug Des Devel Ther. 2015 Jul 31;9:4127-35. doi: 10.2147/DDDT.S86725. eCollection 2015. PubMed PMID: 26257511; PubMed Central PMCID: PMC4527374.
